Condition: Male Breast Cancer · Hormone Receptor-positive Breast Cancer · Hormone Receptor Negative Breast Carcinoma · Sponsor: Jose Pablo Leone
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemaciclib
This description comes directly from the study's public registry record.
Jose Pablo Leone, MD · 617-789-2903 · josep_leone@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill, North Carolina, United States | Recruiting |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pittsburgh Cancer Institute | Pittsburgh, Pennsylvania, United States | Recruiting |
| Vanderbilt Cancer Center | Nashville, Tennessee, United States | Recruiting |
| M. D. Anderson Cancer Center at University of Texas | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05501704